CoChat

Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase

Open access
Gibson, Elizabeth G., Bax, Ben, Chan, Pan F., Osheroff, Neil · 2019 · ACS Infectious Diseases
Cited by 178

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Abstract

Gepotidacin is a first-in-class triazaacenaphthylene novel bacterial topoisomerase inhibitor (NBTI). The compound has successfully completed phase II trials for the treatment of acute bacterial skin/skin structure infections and for the treatment of uncomplicated urogenital gonorrhea. It also displays robust in vitro activity against a range of wild-type and fluoroquinolone-resistant bacteria. Due to the clinical promise of gepotidacin, a detailed understanding of its interactions with its antibacterial targets is essential. Thus, we characterized the mechanism of action of gepotidacin against Staphylococcus aureus gyrase. Gepotidacin was a potent inhibitor of gyrase-catalyzed DNA supercoiling (IC 50 ≈ 0.047 μM) and relaxation of positively supercoiled substrates (IC 50 ≈ 0.6 μM). Unlike fluoroquinolones, which induce primarily double-stranded DNA breaks, gepotidacin induced high levels of gyrase-mediated single-stranded breaks. No double-stranded breaks were observed even at high gepotidacin concentration, long cleavage times, or in the presence of ATP. Moreover, gepotidacin suppressed the formation of double-stranded breaks. Gepotidacin formed gyrase–DNA cleavage complexes that were stable for >4 h. In vitro competition suggests that gyrase binding by gepotidacin and fluoroquinolones are mutually exclusive. Finally, we determined crystal structures of gepotidacin with the S. aureus gyrase core fusion truncate with nicked (2.31 Å resolution) or intact (uncleaved) DNA (2.37 Å resolution). In both cases, a single gepotidacin molecule was bound midway between the two scissile DNA bonds and in a pocket between the two GyrA subunits. A comparison of the two structures demonstrates conformational flexibility within the central linker of gepotidacin, which may contribute to the activity of the compound.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acsinfecdis.8b00315

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • The PyMOL Molecular Graphics System

    DeLano, W. L. (2002) · Medical Entomology and Zoology · Cited by 18,147

  • REFMAC 5 for the refinement of macromolecular crystal structures

    Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M. D., Long, F., & Vagin, A. A. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911001314 · Cited by 8,317

  • Towards automated crystallographic structure refinement with phenix.refine

    Afonine, P. V., Grosse-Kunstleve, R. W., Echols, N., Headd, J. J., Moriarty, N. W., Mustyakimov, M., Terwilliger, T. C., Urzhumtsev, A., Zwart, P. H., & Adams, P. D. (2012) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444912001308 · Cited by 5,511 · cited 1×

    “58 The restraint dictionary for gepotidacin was made with Acedrg.”
    Method
  • HKL-3000: the integration of data reduction and structure solution – from diffraction images to an initial model in minutes

    Minor, W., Cymborowski, M., Otwinowski, Z., & Chruszcz, M. (2006) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444906019949 · Cited by 2,099 · cited 11×

    “The left-hand side (triazaacenaphthylene) of gepotidacin sits in a pocket in the DNA on the twofold axis of the complex (pocket 2D), midway between the two DNA cleavage sites, and the right-hand side (pyranopyridine) sits in a pocket on the twofold axis between the two GyrA subunits (pocket 2A; Figures 11 and 12).”
    BackgroundInfluential
  • DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs

    Pommier, Y., Leo, E., Zhang, H., & Marchand, C. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.04.012 · Cited by 1,829 · cited 11×

    “The left-hand side (triazaacenaphthylene) of gepotidacin sits in a pocket in the DNA on the twofold axis of the complex (pocket 2D), midway between the two DNA cleavage sites, and the right-hand side (pyranopyridine) sits in a pocket on the twofold axis between the two GyrA subunits (pocket 2A; Figures 11 and 12).”
    BackgroundInfluential
  • Mechanism of Quinolone Action and Resistance

    Aldred, K. J., Kerns, R. J., & Osheroff, N. (2014) · Biochemistry · doi:10.1021/bi5000564 · Cited by 1,282 · cited 11×

    “The left-hand side (triazaacenaphthylene) of gepotidacin sits in a pocket in the DNA on the twofold axis of the complex (pocket 2D), midway between the two DNA cleavage sites, and the right-hand side (pyranopyridine) sits in a pocket on the twofold axis between the two GyrA subunits (pocket 2A; Figures 11 and 12).”
    BackgroundInfluentialSelf-citation
  • Type IIA topoisomerase inhibition by a new class of antibacterial agents

    Bax, B. D., Chan, P. F., Eggleston, D. S., Fosberry, A., Gentry, D. R., Gorrec, F., Giordano, I., Hann, M. M., Hennessy, A., Hibbs, M., et al. (2010) · Nature · doi:10.1038/nature09197 · Cited by 860 · cited 11×

    “The left-hand side (triazaacenaphthylene) of gepotidacin sits in a pocket in the DNA on the twofold axis of the complex (pocket 2D), midway between the two DNA cleavage sites, and the right-hand side (pyranopyridine) sits in a pocket on the twofold axis between the two GyrA subunits (pocket 2A; Figures 11 and 12).”
    BackgroundInfluentialSelf-citation
  • Mechanisms of drug resistance: quinolone resistance

    Hooper, D. C., & Jacoby, G. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12830 · Cited by 716 · cited 11×

    “The left-hand side (triazaacenaphthylene) of gepotidacin sits in a pocket in the DNA on the twofold axis of the complex (pocket 2D), midway between the two DNA cleavage sites, and the right-hand side (pyranopyridine) sits in a pocket on the twofold axis between the two GyrA subunits (pocket 2A; Figures 11 and 12).”
    BackgroundInfluential
  • All tangled up: how cells direct, manage and exploit topoisomerase function

    Vos, S. M., Tretter, E. M., Schmidt, B. H., & Berger, J. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3228 · Cited by 650 · cited 11×

    “The left-hand side (triazaacenaphthylene) of gepotidacin sits in a pocket in the DNA on the twofold axis of the complex (pocket 2D), midway between the two DNA cleavage sites, and the right-hand side (pyranopyridine) sits in a pocket on the twofold axis between the two GyrA subunits (pocket 2A; Figures 11 and 12).”
    BackgroundInfluential
  • Mechanisms of fluoroquinolone resistance

    Hooper, D. C. (1999) · Drug Resistance Updates · doi:10.1054/drup.1998.0068 · Cited by 488

Show all 62 references

Cited by

Metadata

Authors
Gibson, E. G., Bax, B., Chan, P. F., & Osheroff, N.
Venue
ACS Infectious Diseases
Published
2019-02-13
Volume
5
Issue
4
Pages
570-581
ISSN
2373-8227 (ISSN-L)
OpenAlex
W2914873171
Cited by
178
References
62
FWCI
4.58
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.